cyrilzakka/clinical-trials huggingface dataset:
Effects of Dry Needling in Patients With Upper Cross Syndrome

The study will be done to evaluate the effectiveness of dry needling of muscles involved in Upper Cross Syndrome. Muscles involved in upper cross syndrome are tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids. Physical assessment of trigger points will locate the target area for dry needling. After pre treatment measurements, dry needling will be performed to treatment group and stretching, hot pack and tens will be apply in control group. Study design will be randomized controlled trial and sample size will be 34 participants. Data will be collected from Riphah Rehabilitation Center. Patients of 20-50 years old with UCS diagnosed through observation and physical examination will be included. Patients with systemic soft tissue and bony diseases will be excluded. Intervention duration will be two session of DNT with two weeks routine management. Basic tools will be Visual analog scale (VAS), Neck Disability Index (NDI) and Goniometry

Dry needling is relatively new method for the management of musculoskeletal pain.Different methods of dry needling, its effectiveness, and physiologic and adverse effects are discussed. Dry needling is a treatment modality that is minimally invasive, cheap, easy to learn with appropriate training, and carries a low risk. The deep method of dry needling has been shown to be more effective than the superficial one for the treatment of pain associated with myofascial trigger points. However, over areas with potential risk of significant adverse events, such as lungs and large blood vessels, we suggest using the superficial technique, which has also been shown to be effective. Questionnaire for assessing the improvement in quality of life is by NDI and ranges like neck flexion/extension, side bending and rotation will be measured by standard goniometry. Neck disability index will use to check the patient's ability to perform his ADL before and after the treatment/control. Data will be collected from Riphah rehab center. Assessed patients of UCS of age 20 to 50 will be the targeted population of this study. Patients with systematic and bony disease excluded from the study. Population having stiff upper back, tight trap and stiff upper thoracic spine have UCS. Ethical guidelines will be followed for both treatment and control group. SPSS version 21 will be use for data analysis with sample size of 34 participants, 17 participants each group that will randomly allocated in treatment/control group.

Eligibility Criteria:
Inclusion Criteria:

* Stiffness and gradual pain in neck and shoulder
* Pain due to Postural Dysfunction
* Trauma or insidious onset

Exclusion Criteria:

* Any systemic soft tissue and bony disease.
* Patient with spinal tuberculosis, spinal fractures, pregnancy, cancer.
* Any recent surgery.
* Patient with any cervical or thoracic problem.
* Patients with any other serious pathology/red flags
Implant-supported Zirconia Partial Dentures With Cantilever

Fifteen partially edentulous patients received 34 implants and were provided 16 zirconia fixed partial prostheses (FPPs) with one cantilever extension replacing mandibular or maxillary missing posterior and lateral teeth. Patients were re-examined up to 4 years.

The investigators consecutively enrolled 15 patients who required dental implant rehabilitation with fixed dental prosthesis. All patients were attended at a private out-patient clinic from 2018 to 2021.The study was conducted in Italy and all procedures respect European laws and regulations.A diagnostic wax-up of the missing teeth was performed on digital casts for each case. Each case was designed using software planning the implant position in the distal part of the edentulous ridge where the bone conditions were more favorable.The surgical procedures were performed according to the protocols given by manufacturers.The implant site was prepared after raising a full-thickness flap. The implant was placed as designed in the digital planning with the support of a surgical guide.The patients were recalled 3-6 months after surgery for a pre-prosthetic evaluation. A healing abutment was placed, and implant stability was proven.Three weeks after second-stage surgery, the definitive digital impression was taken using an intraoral scanner. The prosthetic procedures were performed according to manufacturers' implant system recommendations. All prostheses were designed using CAD software with a connector cross-sectional area of at least 12 mm2. Monolithic zirconia fixed partial dentures were fabricated using a CAD-CAM unit from pre-sintered, pre-shade zirconia blanks . The fixed dentures were characterized with ceramic-based colors. The screw-retained zirconia prosthesis were subsequently inserted, and a check of the occlusion was performed.The patients get a baseline examination after 1-3 weeks of final prosthesis insertion. Aesthetics, proximal contacts, and occlusion were modified when needed following a careful examination. Patients were recalled at least once a year to assess the restorations functionally and aesthetically, peri-implant tissues, and implant health status. An individual maintenance program with regular dental hygiene sessions was performed during the entire study period for every patient, and an x-ray was taken at the 2-year follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Good health according to the System of the American Society of Anesthesiology
* Aged older than 18 years
* No general medical contraindication for implant therapy
* Two or more missing teeth from the canine to the second molar
* Good periodontal health or treated periodontitis

Exclusion Criteria:

* Smoking more than 15 cigarettes a day
* Untreated periodontitis
* Pregnancy
* Acute infections
* Keratinized mucosal tissue less than 2 mm.
Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)

The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19), that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The more frequent presentation is acute respiratory distress syndrome (ARDS).

To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry receptor.

ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly modified when SRAA inhibitors are administred to patients, and ACE2 level increases particularely with Angiotensin II Receptor blockers (ARA2) use.

The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2 infection admitted to the intensive care unit (ICU).

COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission, day 3 and day 7.

The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19), that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The more frequent presentation is acute respiratory distress syndrome (ARDS).

To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry receptor.

ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly modified when SRAA inhibitors are administred to patients, and ACE2 level increases particularely with Angiotensin II Receptor Blockers (ARA2) use.

The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2 infection admitted to the intensive care unit (ICU).

COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission, day 3 and day 7.

Eligibility Criteria:
Inclusion Criteria:

* admission to the intensive care unit,
* with a proven COVID infection, responsible for acute respiratory failure
* agree with participation to the study.

Exclusion Criteria:

* aged under 18
* under legal protection
* pregnant or breastfeeding
Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma

The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine (Cyspera) alone in the treatment of melasma.

The main questions it aims to answer are

* If melasma treatment with topical cysteamine cream is more effective when used with the Clear \& Brilliant® Permea laser
* The safety \& efficacy of melasma treatment in various skin types using the Clear \& Brilliantt® Permea laser in combination with topical cysteamine.

Participants will

* Come into our office for an initial screening appointment to determine if participant is eligible for the study
* Come in for 3 laser treatments, 4 weeks apart, on 1 side of the face
* Use the study provided Cyspera topical cream every day on the entire face for the 12 weeks on the study.

Researchers will compare the side of the participants face not treated with laser to the side of the face treated with laser. The participants will be using Cyspera on both sides of their face.


Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects of Skin Type I-VI females.
* Subjects must be between 18 and 74 years of age, and must have visible melasma on the face.
* Subjects must read, understand, and sign the Informed Consent.
* Subjects must be willing and able to comply with all follow-up requirements.

Exclusion Criteria:

* Subjects must not have active or localized or systemic infections.
* Subjects must not be immunocompromised.
* Subjects must not have a coagulation disorder, and must not be using anticoagulation -medications.
* Subjects must not have history of surgical or cosmetic treatment, including prior skin lightening agents, microneedling or microdermabrasion, or laser or light-based therapies, to the planned treatment areas in the prior 8 weeks.
* Subjects must not have photosensitivity or allergy.
* Subjects must not be mentally incompetent.
* Subjects must not be pregnant or breastfeeding.
* History of skin cancer or pre-cancerous lesions in the treatment area
* Subjects must not be currently using aspirin or antioxidants.
* Subjects must not refuse to sign the Informed Consent document and/or refuse to comply with all follow-up requirements.
* Subjects must never have had gold therapy.
* Subjects must never have had radiation therapy to the face. Recent or current suntan or sunburn within 2 weeks.
* Clinically dysplastic nevi in the treatment area.
* Subjects must not have had collagen, other methods of tissue augmentation, botox, chemical peels, dermabrasion, or resurfacing within the last year.
* Oral retinoid (Accutane or Soriatane) or photosensitizing drugs, e.g. Declomycin®, a tetracycline with light absorption in the range of 400 to 450 nm use within 24 months of study entry.
* Topical retinoid therapy on face within one month of study entry.
* History of keloids or hypertrophic scars
* A history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins, or photodermatosis.
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus

Intrathecal morphine causes intense itching which is very bothersome. Nalbuphine antagonizes this effect when given intravenously. This trial is to find out if nalbuphine added to intrathecal morphine has an effect on morphine related pruritus while still maintaining adequate analgesia.

The study will be performed in MiniaUniversity Hospitals, after obtaining approval from the local ethics committee. All patients will have a peripheral IV cannula 18 G inserted; standard non-invasive monitors will be applied. Patients undergoing major abdominal surgery will be divided into 2 groups to receive intrathecal morphine 300 micrograms with or without nalbuphine 1mg prior to anesthesia. General anesthesia is then given to patients.

Eligibility Criteria:
Inclusion Criteria:

* Male and female patients.
* Age 18-80yrs.
* Elective major abdominal surgery under general anesthesia.

Exclusion Criteria:

* Refusal to participate.
* Skin or systemic disease with itching. Any condition which precludes performing spinal injection
Wearable Noninvasive Positive Pressure Ventilation Device in COPD

The objective is to assess the impact of a wearable Noninvasive Positive Pressure Ventilation, on physical activity and quality of life in patients with severe COPD, complaining of dyspnea.

In order to avoid the occurrence of uncomfortable dyspnea, patients with Chronic Obstructive Pulmonary Disease (COPD) are locked in a vicious circle of inactivity and social isolation which profoundly affects their quality of life and prognosis. A new wearable non invasive positive pressure ventilation device has been recently proposed; it can be used by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea- recovery time. The investigators hypothesize that this system, in reducing the inconvenience caused by dyspnea, would stimulate a more active lifestyle and improve quality of life. Their objective is to assess the impact of this device on physical activity and quality of life in patients with severe COPD, complaining of dyspnea.

In this open study with no control group, participants will use the device at their convenience, according to their needs in daily life and for 4 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Patients with stable severe COPD (with FEV1 ≤50% predicted)
* Patients with mMRC score \> ou = 2.

Exclusion Criteria:

* Exacerbate within a month prior.
* Using other non invasive ventilation device \> 15h per day.
* Have musculoskeletal or neuromuscular problem affecting balance and walking.
* Have cognitive problem affecting comprehension of the different évaluations or questionnaires.
* Have recently participated in physical training or rehabilitation program (≤ 3 months).
* Medical contra-indication to NIV.
* Evolutionary pathologies (excluding COPD) may be life-threatening in the short term (1 year) (cancer, neuromuscular disease rapidly changing).
* Simultaneously enrolled in an other clinical trial.
* Not affiliated to social security.
* Person deprived of liberty, major protected by law.
Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension

To compare effectiveness of oral labetalol and oral nifedipine for management of postpartum hypertension.

A comparison of oral labetalol and oral nifedipine for management of postpartum hypertension. Which drug is more effective in lowering blood pressures in patient with postpartum hypertension.

Eligibility Criteria:
Inclusion Criteria:

* all women with postpartum hypertension as a continuation of pregnancy induced hypertension,eclampsia, pre-eclampsia or new onset de-novo postpartum hypertension,of any parity.
* age group between 18-48.
* after informed consent.

Exclusion Criteria:

* all women with chronic hypertension, uncontrolled and un treated medical disorders will be excluded.
* conditions in which drugs labetalol and nifedipine is contraindicated.
Prone Position and Renal Resistive Index

Patients suffering from Acute Respiratory Distress Syndrome (ARDS) with a prone position (PP) indication will benefit from measurements of renal resistive index, intra-abdominal pressure (IAP), urinary oxygen tension (uPO2) and ventilatory mechanics in supine position (baseline IAP), after 2 hours in PP at the current IAP value, thirty minutes after patients' abdomen suspension in order to resume baseline IAP and after patients' are turned back to supine position.


Eligibility Criteria:
Inclusion Criteria:

* ARDS patients according to Berlin criteria, intubated, mechanically ventilated
* with PaO₂/FiO₂ \< 150 mmHg,
* neuromuscular blockade
* with an indication of PP done by the physician in charge
* possibility to differ PP for one hour
* patients should be hemodynamically stable since at least 4 hours

Exclusion Criteria:

* Pregnant or breast-feeding women
* legal protection, no social security affiliation
* PP contra-indication
* nasogastric tube contra-indication
* extra corporeal membrane oxygenation
* acute kidney injury at inclusion according to K-DIO criteria, chronic kidney disease defined as an estimated glomerualr filtration rate less than 30 ml/min/1.73m², kidney transplantation, renal artery stenosis, solitary kidney, albuminuria \> 1.25 mg/ml
* cardiac arrhythmia
* obesity
* advanced cirrhosis
Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral

Primary Objective:

To demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd PHDESILSTYFL.


Eligibility Criteria:
Inclusion criteria:

* Phototype Skin I,II, III e IV Integral skin test in the region
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Exclusion criteria:

* Lactation or pregnancy
* Use of Antiinflammatory 30 days and/or immunossupression drugs for until 3 months before volunteers selection
* Disease which can cause immunosuppresion, such as diabetes, HIV
* Use of Antihistamines 30 days before selection
* Personnel history of atopy
* History of sensitivity or irritation for topic products
* Cutaneous active disease (local and/or general) which can modify the study results
* Use of new drugs and/or cosmetics during the study
* Cutaneous reactive
* Previous participation in studies using the same product in test
* Volunteer which has immunodeficiency congenital or acquired
* Relevant history or confirmation of alcohol or other drugs abuse
* Intolerance detected or suspected for some component of the sample tested
* Medecin or sponsor employees or their close family

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
EPIC: Evaluation of Pharmacy-based Identification and Treatment of HCV

The research project aims to understand how pharmacies can be involved in the identification and treatment of hepatitis C (hep C). The study will look at the effectiveness of hep C testing and treatment through pharmacies with support from the Cool Aid Community Health Centre (CACHC). The study will also evaluate the readiness of pharmacies to take on these extra tasks at the pharmacy. This information will be used to develop future strategies to better detect, treat and prevent hep C.

The primary objective of this project is to decrease barriers to care for hepatitis C (HCV) treatment for people who use drugs through the use of rapid diagnostic testing technologies, and task shifting HCV testing and treatment follow up to include trained pharmacy staff. Secondary objectives are to evaluate interest, readiness, and effectiveness of community-based pharmacies as a location for the screening and treatment of HCV.

A prospective, longitudinal interventional cohort design will be used to enrol people who access community-based pharmacies and have tested for HCV RNA. Persons with untreated chronic HCV infection will receive direct acting antiviral treatment. This is a trial of pharmacist-led HCV testing and treatment versus conventional care in HCV positive patients.

Eligibility Criteria:
Inclusion Criteria:

1. Able to provide informed consent
2. Age \> 18 years old
3. Documented HCV RNA test, interested in being tested for HCV antibody or at risk for HCV (ie. "Baby boomers": anyone born between 1945-1965, anyone known to currently (past 6 months) or have a history of injecting drugs, including anyone receiving Opiate Agonist Therapy (OAT), any gay or bisexual men who have sex with men (gbMSM))

Exclusion Criteria:

1) Declined to provide informed consent
A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

This is a 96 week study to determine if UK- 453,061 in combination with Truvada is as efficacious, safe and tolerable as efavirenz in combination with Truvada in HIV-1 infected patients who have not been previously treated with antiretroviral drugs.


Eligibility Criteria:
Inclusion Criteria:

* Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
* HIV 1 RNA viral load of greater then 1,000 copies/mL
* Negative urine pregnancy test.

Exclusion Criteria:

* Suspected or documented active, untreated HIV-1 related opportunist infection or other condition requiring acute therapy at the time of randomization.
* Subjects with acute Hepatitis B and/or C within 30 days of randomization.
* Absolute CD4 count \<200 cells/mm3.
Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation

Ginseng has been used for many years in a wide array of anecdotal medicinal properties. Animal and limited clinical research points to the vascular effects of Korean Red Ginseng (KRG). The present project aims to assess the efficacy of KRG and contribution of its factionated components on various indices of vascular function in healthy individuals. Our primary objective is to compare the acute effects of KRG and placebo on endothelial function. Moreover, our secondary objective is to evaluate the effect of isolated KRG factions on arterial stiffness, blood pressure and vasoactive markers. We hypothesize that (1) consumption of KRG will cause an improvement in endothelial function in healthy individuals, as compared to placebo; (2) consumption of KRG will cause an improvement in arterial stiffness and blood pressure in healthy individuals, as compared to placebo; (3) the ginsenoside faction of KRG is primarily responsible for the anticipated vascular effects.


Eligibility Criteria:
Inclusion Criteria:

* Age: between 18 and 70 years of age
* Healthy individuals (absence of major illnesses)

Exclusion Criteria:

* Primary hypertension (defined by the use of antihypertensive agents or a seated systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than 90mmHg)
* Secondary hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg)
* Grade 3 hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg)
* Diabetes
* Chronic kidney disease
* Liver disease
* Estrogen-sensitive cancer
* Heavy alcohol use
* Bleeding disorders
* Planned surgery
* Angina
* CHF
* Coronary revascularization
* Peripheral vascular disease
* Coronary/cerebrovascular event in the last 6 months
* Prescriptions of MAO inhibitors, SSRIs, diuretics, sympathomimetics, herbal therapies, medication affecting nitric oxide synthesis, and/or anticoagulent medications within the last 6 months
* Sensitivity to any of the ingredients in the treatments or placebo
* Chronic use of or frequent prescriptions for NSAIDs
* Women of childbearing potential must not be pregnant or breast-feeding